Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > Looking back at 2020 outlook by John D. Vandermosten
View:
Post by Mole101 on Jun 07, 2021 9:46pm

Looking back at 2020 outlook by John D. Vandermosten

Summary
ProMIS has continued to advance its preclinical programs and enter into diagnosting testing collaborations to detect both coronavirus and Alzheimer s Disease. Parallel with these endeavors is the continued interaction with the scientific, investment and corporate community to garner KOL support, financing and partnerships. Management has refined its message highlighting the need to focus on the toxic forms of misfolded proteins that are the root cause of neurodegenerative disease and the importance of biomarkers that can rapidly and inexpensively demonstrate efficacy. We continue to be impressed with ProMIS discovery platforms and their ability to identify unique features of toxic misfolded proteins and their ability to be repurposed to identify targets for the coronavirus. We believe that a pharmaceutical partner deal or large investment will allow the company to advance its candidates into the clinic.
ProMIS represents an attractive opportunity to gain exposure to a disorder with no other approved disease modifying therapies. There are almost six million people in the US and over 30 million people outside of the US suffering from AD. Additionally, there is a larger population with mild cognitive impairment (MCI) and pre- Alzheimer s which may benefit even more from toxic oligomer sequestering therapy. The path forward is relatively clear with other assets setting the precedent for trial design and potentially accelerated approaches using biomarkers suggested by regulatory agencies. There is also substantial opportunity for drug development in PD, MSA and ALS.
Due to the uncertain environment regarding to aducanumab, the investment community is waiting to invest new money in A programs. We expect to see a response by the FDA to Biogen s drug by March of next year, which may bring attention back to the A space.
    ProMIS has a number of recent and upcoming milestones related to development of its pipeline which we
 summarize below.
   We continue to believe in the potential of PMN310 and the other
 candidates in development and the tremendous opportunity in AD and other neurodegenerative diseases due to the
 lack of effective therapies and the magnitude of the need. We maintain our target price of $5.50.


https://s27.q4cdn.com/906368049/files/News/2020/Zacks_SCR_Research_08242020_T.PMN_Vandermosten.pdf
 
Comment by Thenorth1990 on Jun 07, 2021 10:24pm
I am not sure whether he still covers PMN, he pretty much tweets about every other company and has been quite about since October last year. Anyways we did put our money way before these Boston guys and fda green flag , so I do really hope we get somewhere soon . And now the plus side is we have serology too . Cheers to all of us who didn't cash out at uncertain times
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities